GUTS Fractyl Health Inc.
- Stocks
- Healthcare
- NASDAQ: GUTS
Price (delayed)
$1.005
Market cap
$50.54M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.07
Enterprise value
$89.97M
We are a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. Despite advances in treatment over the last
Highlights
GUTS's gross margin is up by 43% year-on-year and by 22% since the previous quarter
The EPS has surged by 90% year-on-year but it has declined by 11% since the previous quarter
Fractyl Health's equity has plunged by 126% YoY
GUTS's quick ratio has dropped by 86% year-on-year and by 54% since the previous quarter
Key stats
What are the main financial stats of GUTS
Market
Valuations
Earnings
Shares outstanding
50.29M
Market cap
$50.54M
Enterprise value
$89.97M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2,899.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5,292.2
Revenue
$17,000
Gross profit
$10,000
Operating income
-$99.84M
Net income
-$99.77M
EBIT
-$99.77M
EBITDA
-$97.26M
Free cash flow
-$82.34M
Per share
Balance sheet
Liquidity
EPS
-$2.07
EPS diluted
-$2.07
Free cash flow per share
-$1.68
Book value per share
-$0.37
Revenue per share
$0
TBVPS
$1.26
Total assets
$62.01M
Total liabilities
$80.22M
Debt
$61.72M
Equity
-$18.21M
Working capital
$4.86M
Debt to equity
-3.39
Current ratio
1.22
Quick ratio
1.02
Net debt/EBITDA
-0.41
Margins
Efficiency
Dividend
EBITDA margin
-572,135.3%
Gross margin
58.8%
Net margin
-586,864.7%
Operating margin
-587,305.9%
Return on assets
-105%
Return on equity
-596.4%
Return on invested capital
-118.8%
Return on capital employed
-248.3%
Return on sales
-586,864.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GUTS stock price
How has the Fractyl Health stock price performed over time
Intraday
-0.5%
1 week
3.32%
1 month
-35.99%
1 year
-54.93%
YTD
-51.21%
QTD
-37.96%
Financial performance
How have Fractyl Health's revenue and profit performed over time
Revenue
$17,000
Gross profit
$10,000
Operating income
-$99.84M
Net income
-$99.77M
Gross margin
58.8%
Net margin
-586,864.7%
The revenue has dropped by 86% year-on-year and by 72% since the previous quarter
The company's net income has shrunk by 80% YoY and by 12% QoQ
GUTS's gross profit has dropped by 80% year-on-year and by 66% since the previous quarter
GUTS's gross margin is up by 43% year-on-year and by 22% since the previous quarter
Price vs fundamentals
How does GUTS's price correlate with its fundamentals
Growth
What is Fractyl Health's growth rate over time
Valuation
What is Fractyl Health stock price valuation
P/E
N/A
P/B
N/A
P/S
2,899.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5,292.2
The EPS has surged by 90% year-on-year but it has declined by 11% since the previous quarter
Fractyl Health's equity has plunged by 126% YoY
The revenue has dropped by 86% year-on-year and by 72% since the previous quarter
The price to sales (P/S) is 48% higher than the last 4 quarters average of 1964.6
Efficiency
How efficient is Fractyl Health business performance
Fractyl Health's ROE has plunged by 161% from the previous quarter
GUTS's return on invested capital has dropped by 91% year-on-year and by 16% since the previous quarter
The ROA has plunged by 76% YoY and by 37% from the previous quarter
Dividends
What is GUTS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GUTS.
Financial health
How did Fractyl Health financials performed over time
Fractyl Health's total assets is 23% lower than its total liabilities
GUTS's quick ratio has dropped by 86% year-on-year and by 54% since the previous quarter
The current ratio has shrunk by 84% YoY and by 51% QoQ
Fractyl Health's debt to equity has shrunk by 135% QoQ
Fractyl Health's equity has plunged by 126% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.